Vitamin D and lung cancer

References

• Zhou W, Heist RS, Liu G et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev.14(10), 2303–2309 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou W, Heist RS, Liu G et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol.25(5), 479–485 (2007).
   PubMed Web of Science ®Google Scholar
• Rassnick KM, Muindi JR, Johnson CS et al. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother. Pharmacol.62(5), 881–891 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu K, Bruce D, Austin N et al. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J. Bone Miner. Res.23(8), 1343–1348 (2008).
   PubMed Web of Science ®Google Scholar
• Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther.3(3), 373–381 (2004).
   PubMed Web of Science ®Google Scholar
• Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr.89(5), 552–572 (2003).
   PubMed Web of Science ®Google Scholar
• DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am. J. Clin. Nutr.80(Suppl. 6), 1689S–1696S (2004).
   PubMed Web of Science ®Google Scholar
• Shaffer PL, Gewirth DT. Structural basis of VDR-DNA interactions on direct repeat response elements. EMBO J.21(9), 2242–2252 (2002).
   PubMed Web of Science ®Google Scholar
• Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev.26(5), 662–687 (2005).
   PubMed Web of Science ®Google Scholar
• Chapuy MC, Preziosi P, Maamer M et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int.7(5), 439–443 (1997).
   PubMed Web of Science ®Google Scholar
• Uitterlinden AG, Fang Y, Van Meurs JB et al. Genetics and biology of vitamin D receptor polymorphisms. Gene338(2), 143–156 (2004).
   PubMed Web of Science ®Google Scholar
• Bouillon R, Verlinden L, Eelen G et al. Mechanisms for the selective action of Vitamin D analogs. J. Steroid Biochem. Mol. Biol.97(1–2), 21–30 (2005).
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N. Engl. J. Med.357(3), 266–281 (2007).
   PubMed Web of Science ®Google Scholar
• Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer7(9), 684–700 (2007).
   PubMed Web of Science ®Google Scholar
• Eelen G, Verlinden L, van Camp M et al. The effects of 1α,25-dihydroxyvitamin D3 on the expression of DNA replication genes. J. Bone Miner. Res.19(1), 133–146 (2004).
   PubMed Web of Science ®Google Scholar
• Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res.56(2), 264–267 (1996).
   PubMed Web of Science ®Google Scholar
• McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem.276(28), 26365–26373 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng HT, Chen JY, Huang YC et al. Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J. Cell Biochem.98(6), 1450–1456 (2006).
   PubMed Web of Science ®Google Scholar
• Hershberger PA, Modzelewski RA, Shurin ZR et al. 1,25-dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res.59(11), 2644–2649 (1999).
   PubMed Web of Science ®Google Scholar
• Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res.57(17), 3759–3764 (1997).
   PubMed Web of Science ®Google Scholar
• Trump DL, Hershberger PA, Bernardi RJ et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol.89–90(1–5), 519–526 (2004).
   PubMed Web of Science ®Google Scholar
• Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1α,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin. Cancer Res.7(12), 4164–4173 (2001).
   PubMed Web of Science ®Google Scholar
• Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev.10(2), 142–153 (1996).
   PubMed Web of Science ®Google Scholar
• Jemal A, Thun MJ, Ries LA et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl Cancer Inst.100(23), 1672–1694 (2008).
   PubMed Web of Science ®Google Scholar
• Kilkkinen A, Knekt P, Heliövaara M et al. Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol. Biomarkers Prev.17(11), 3274–3278 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou W, Heist RS, Liu G et al. Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol. Biomarkers Prev.15(11), 2239–2245 (2006).
   PubMed Web of Science ®Google Scholar
• Higashimoto Y, Ohata M, Nishio K et al. 1α, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res.16(5A), 2653–2659 (1996).
   PubMed Web of Science ®Google Scholar
• McElwain MC, Dettlebach MA, Modzelewski RA et al. Antiproliferative effects in vitro and invivo of 1, 25- dihydroxyvitamin D3 and a vitamin D3 analogue in squamous cell carcinoma model system. Mol. Cell. Differ.3, 31–50 (1995).
   Google Scholar
• Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol. Immunother.41(1), 37–45 (1995).
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1α,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis26(6), 1044–1054 (2005).
   PubMed Web of Science ®Google Scholar
• Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol.181(10), 7090–7099 (2008).
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Parwani AV, Hershberger PA, Lenzner DE, Weissfeld JL. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J. Steroid Biochem. Mol. Biol.123(1–2), 30–36 (2011).
   PubMed Web of Science ®Google Scholar
• Menezes RJ, Cheney RT, Husain A et al. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol. Biomarkers Prev.17(5), 1104–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Chen G, Kim SH, King AN et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin. Cancer Res.17(4), 817–826 (2010).
   PubMed Web of Science ®Google Scholar
• Parise RA, Egorin MJ, Kanterewicz B et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int. J. Cancer119(8), 1819–1828 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol.57(2), 234–240 (2006).
   PubMed Web of Science ®Google Scholar
• Kim B, Lee HJ, Choi HY et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res.67(15), 7431–7438 (2007).
   PubMed Web of Science ®Google Scholar
• Zitzelsberger H, Engert D, Walch A et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br. J. Cancer84(2), 202–208 (2001).
   PubMed Web of Science ®Google Scholar
• Fridlyand J, Snijders AM, Ylstra B et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer6, 96 (2006).
   PubMed Web of Science ®Google Scholar
• Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer45(1), 31–41 (2006).
   PubMed Web of Science ®Google Scholar